Actinium Pharmaceuticals Inc. (ATNM) Uses Alpha Emitter to Treat Early & Late-Stage Leukemia

• Report rights infringement
• published: 08 Aug 2014
• views: 6068

"The RedChip Money Report: Small Stocks, Big Money" host Dave Gentry interviews Sandesh Seth, Chairman of Actinium Pharmaceuticals Inc. (NYSE MKT:ATNM), a clinical-stage biopharmaceutical company that uses alpha emitter technology that targets early and late stage leukemia. "The RedChip Money Report"™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The weekly program airs on Fox Business as well as Bloomberg UK, Bloomberg Europe, and Bloomberg Asia. For more information, visit: http://www.redchip.com/tv Show Transcript: Actinium Pharmaceuticals. Another RedChip Client company on the NYSE. This is a biotech company with proprietary alpha and beta emitter technology. Targeting early and late stage leukemia. You'll learn in a few minutes what we mean by alpha and beta emitter technology Its one of only three companies in the world by the way, with this alpha emitter technology. Sloan Memorial Cancer Center owns over 20% of this company. This could be our next Galectin THerapeutics. That stock, as you recall, appreciated over 1000% since airing on my show in late 2012 Now, here to tell us more about Actinium is the Chairman of the Board Sandesh Seth. Seth thanks for being with us today. [Seth] Well thanks for having me Dave. [Dave] You have a very exciting company. You are in the business of fighting leukemia. You just raised $16M. You're a NYSE company. You have two trials. I wanna talk first about your Phase 1 Phase 2 trial and that technology. [Seth] Sure, absolutely. We nuke cancer cells using a combination of radiation and antibodies which act as the missile that get the radiation to the cancer cell. Our latest stage, most advanced program. Is a drug candidate called Iomab which prepares cancer patients who are going in for a bone marrow transplant it enables them to get a bone marrow transplant by nuking the cancer cell in a very clean and efficient way. That drug candidate, Iomab-B will begin a clinical trial in the first half of 2015 and we expect to be able to complete that trial toward the tail end of 2016 and file with the FDA. [Dave] What's the end point on that? trial? [Seth] The endpoint is very simple Dave, it is cancer free survival six months after a bone marrow transplant. has taken hold. [Dave] Whats the lead hospital on this trial? [Seth] Several lead hospitals, Dave. Some of the foremost cancer centers and transplant centers in the United States. In no order of importance Fred Hutchinson Cancer Center, MD Anderson, Sloan Kettering, Columbia and Baylor Sloan Kettering has been a big supporter of the company. Our core technology indeed has come from Sloan Kettering's labs. our IP, and they have been a big producer of data for our early results. In fact, they were the people that produced the data for our first generation product, on the basis of which our earlier stage product Iomab-A is built on. [Dave] The market for that drug is a as I understand, is about $800M. So it is a very large market opportunity. When will you complete the trial? [Seth] We will complete the trial, if everything goes well, toward the end of 2016 for the first indication. Which as you correctly said is an $800M opportunity. [Dave] and that indication is? [Seth] That indication is acute Myeloid Leukemia. which is the deadliest cancer known to man. However, if you go on our website, you will find some of the top doctors in the country in a video talking about the longer term potential of Iomab-B And it is indeed a drug that is applicable to other blood cancers, which then translates to a multi-billion dollar drug revenue opportunity. [Dave] Lets go to your Phase 1 Phase 2 trial. You are one of only three companies in the world with this alpha emitter technology. Algeta being the other one. Which was bought for $2.8B, i think? [Seth] About that. About $2.9 [Dave] Based primarily on that technology. So talk to us about this trial and define for us, alpha emitter technology. What is an alpha emitter? [Seth] Absolutely, an alpha emitter, is a type of radiation. It is somewhat like x-ray radiation, which is gamma radiation. So in fact you have, these units of energy or particles that have an extremely powerful destructive, or penetrating power. And they can be used for various uses. In our case. In our case, we use it to destroy cancer cells Actimab-A is for initial use in patients that have an earlier stage leukemia. It is a second generation drug Dave which means we have a large party of data, on a very similar drug that we chose not to move forward with, because it was very expensive. Actimab-A is a lot cheaper, and it is about 500x more powerful and it is in a trial which we expect to release initial results on in December. [Dave] and how many patients in this trial? [Seth] overall there intended to be about 65 patients all in.